Serum Neuroglobin and Nogo-A Concentrations in Acute Traumatic Brain Injury
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02229643|
Recruitment Status : Completed
First Posted : September 1, 2014
Last Update Posted : August 16, 2016
|Condition or disease|
|Traumatic Brain Injury|
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||34 participants|
|Target Follow-Up Duration:||6 Months|
|Official Title:||Neuroglobin and Nogo-A as Biomarkers for the Prognosis of Closed Traumatic Brain Injury|
|Study Start Date :||May 2012|
|Actual Primary Completion Date :||June 2013|
|Actual Study Completion Date :||June 2014|
Traumatic brain injury
Patients delivered within 4 h whose highest abbreviated injury score (AIS) was 3 or less (other than head injury) were considered to be isolated traumatic brain injury cases and were included in this study.
- Glasgow Outcome Scale scores [ Time Frame: 6 months ]Glasgow Outcome Scale 1 = death; Glasgow Outcome Scale 2 = vegetative state; Glasgow Outcome Scale 3 = severe neurological deficit; Glasgow Outcome Scale 4 = mild neurological deficit and Glasgow Outcome Scale 5 = premorbid level of functioning or completely recovery. Unfavorable outcome was defined as a Glasgow Outcome Scale score of ≤ 3, and favorable outcome was defined as a Glasgow Outcome Scale score of > 3.
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02229643
|Shanghai Sixth People's Hospital|